Tralokinumab (new indication: atopic dermatitis, patients aged 12 to < 18 years)

Subject:

• Active Substance: Tralokinumab
• Name: Adtralza®
• Therapeutic area: Atopic dermatitis
• Pharmaceutical company: LEO Pharma GmbH

Time table:

• Start: 15.11.2022
• Final decision by G-BA: 12.05.2023

Final decision:

• No additional benefit proved